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The most common form of heart failure occurs with
normal systolic function and often involves cardiac
hypertrophy in the elderly. To clarify the biological
mechanisms that drive cardiac hypertrophy in aging,
we tested the influence of circulating factors using
heterochronic parabiosis, a surgical technique in
which joining of animals of different ages leads to a
shared circulation. After 4 weeks of exposure to the
circulation of young mice, cardiac hypertrophy in
old mice dramatically regressed, accompanied by
reduced cardiomyocyte size andmolecular remodel-
ing. Reversal of age-related hypertrophy was not
attributable to hemodynamic or behavioral effects
of parabiosis, implicating a blood-borne factor.
Usingmodified aptamer-based proteomics, we iden-
tified the TGF-b superfamily member GDF11 as a
circulating factor in young mice that declines with
age. Treatment of old mice to restore GDF11 to
youthful levels recapitulated the effects of parabiosis
and reversed age-related hypertrophy, revealing a
therapeutic opportunity for cardiac aging.
INTRODUCTION
Among the diseases and disorders associated with advancing
age, one of the most debilitating is the loss of normal cardiac
function leading to heart failure. Heart failure affects approxi-
mately 1% of individuals over 50 and over 5% of individuals
over 75. With the ongoing steep rise in the proportion of elderly
individuals within our population (Schocken et al., 2008), age-
related heart failure is becoming increasingly prevalent.828 Cell 153, 828–839, May 9, 2013 ª2013 Elsevier Inc.Most age-related heart failure occurs in the setting of normal
systolic function and is called ‘‘diastolic heart failure,’’ in contrast
to ‘‘systolic heart failure’’ (Aurigemma, 2006). Although progress
has been made in the treatment of systolic heart failure, with
substantial improvements in outcome over the past two
decades, progress in treating diastolic heart failure has been
much more elusive (Hunt et al., 2009). Indeed, one can argue
that there are no specific therapies for patients who experience
the ventricular ‘‘stiffening’’ associated with the diastolic dysfunc-
tion that accompanies aging (Kitzman and Daniel, 2007).
Emerging evidence indicates that systemic factors profoundly
influence tissue aging. Some of these data have emerged from
the experimental model of parabiosis, which was first developed
in the 19th century (Finerty, 1952). In parabiosis, two mice are
surgically joined, such that they develop a shared blood circula-
tion with rapid and continuous exchange of cells and soluble
factors at physiological levels through their common circulatory
system (Wright et al., 2001). The pair of animals may be the
same age (isochronic parabionts) or different ages (hetero-
chronic parabionts). Because parabiotic mice are connected
solely through their common circulation, parabiosis is a powerful
model to determine whether circulating factors can alter
tissue function (Balsam et al., 2004; Brack et al., 2007;
Conboy et al., 2005; Eggan et al., 2006; Ruckh et al., 2012; Sher-
wood et al., 2004; Villeda et al., 2011; Wagers et al., 2002;
Wright et al., 2001). Heterochronic parabiosis experiments sug-
gest that blood-borne signals from a young circulation can
significantly impact the function of aging tissues, as indicated
by the restoration of appropriate activation and function of
endogenous, ‘‘old’’ skeletal muscle satellite cells and successful
muscle repair after injury following exposure to a ‘‘youthful’’
systemic milieu (Conboy et al., 2005). Conversely, exposing a
young mouse to an old systemic environment can inhibit
myogenesis (Brack et al., 2007) and neurogenesis (Villeda
et al., 2011) in the young mouse.
Figure 1. Heterochronic Parabiosis Reverses Age-Related Cardiac
Hypertrophy
(A) Experimental scheme. Pairs of young isochronic, heterochronic, and old IP
mice were generated. Four weeks after parabiosis surgery, mice were
euthanized and tissues harvested for analysis.
(B) Reduced heart size in old mice exposed to a young circulation for 4 weeks
is shown. Trichrome-stained cross-sections at midventricle are presented.
(C) Graph represents the heart weight-to-tibia length ratio after 4 weeks of
parabiosis. The heart weight-to-tibia length ratio was significantly lower in old
mice exposed to a young circulation (O-HP) compared to old mice exposed to
an old circulation (O-IP) for 4 weeks and to old unpairedmice (O). No significant
difference was observed when comparing old isochronic to old unpaired mice
or when comparing any of the young groups.
Data are shown as mean ± SEM. See also Figure S1.Cardiachypertrophy isaprominentpathological featureof age-
related diastolic heart failure (Aurigemma, 2006). Here, using a
parabiosis model, we demonstrate that age-related cardiachypertrophy can be reversed by exposure to a young circulatory
environment. These experiments reveal that the cardiac hyper-
trophy of aging is at least in part mediated by circulating factors
and led to the discovery that systemic growth differentiation
factor 11 (GDF11), a TGF-b family member, can reverse age-
related cardiac hypertrophy. These data suggest that at least
one pathologic component of age-related diastolic heart failure
is hormonal in nature and reversible.
RESULTS
Heterochronic Parabiosis Reverses Age-Related
Cardiac Hypertrophy
We hypothesized that circulating factors specific to a young
mouse might reverse cardiac aging. To test this hypothesis, we
generated heterochronic parabiotic (HP) pairs, in which young
female C57BL/6 mice (Y-HP, 2 months) were surgically joined
to old partners (O-HP, 23 months), and compared these to iso-
chronic parabiotic (IP) pairs (young-young [Y-IP] or old-old
[O-IP]), joined at identical ages, and to age- and sex-matched
unpaired mice as controls (young [Y] and old [O]) (Figure 1A).
Cardiac aging in C57Bl/6 mice recapitulates human cardiac
aging, including development of age-related cardiac hypertro-
phy (Dai et al., 2009) in a gender-independent fashion. Parabiotic
pairs were maintained for 4 weeks before analysis, and con-
genic markers were used to distinguish blood cells from aged
(CD45.2+) versus young (CD45.1+) partners (Wright et al.,
2001). This strategy allowed us to monitor blood chimerism in
the pairs; however, because old CD45.1+ mice are not commer-
cially available, we used only CD45.2+ mice to generate iso-
chronic old pairs. Mice were euthanized 4 weeks after joining,
and cross-circulation was confirmed in most of the pairs
(>90%) bymeasuring the frequency of donor-derived blood cells
from one partner (CD45.1+) in the blood or spleen of the other
partner (CD45.2+) (Figure S1 available online).
The striking effect of a young circulation on old hearts was
immediately apparent on visual inspection. Hearts from old
mice exposed to a young circulation (O-HP) for 4 weeks were
noticeably smaller than hearts from O-IP mice. This observation
was confirmed by a blinded comparison of short-axis histological
sections taken fromthemidventricle (Figure1B).Wealsoweighed
the hearts at the time of sacrifice and normalized cardiacmass to
tibia length, a standard method that corrects for differences in
body frame size (Yoshioka et al., 2007) and that is more appro-
priate than normalization to body weight when using older mice
(Jackson et al., 2012; Yin et al., 1982). The heart weight-to-tibia
length ratiowas significantly lower in oldmice exposed to a young
circulation (O-HP) compared to oldmice exposed to an old circu-
lation (O-IP) after 4 weeks of parabiosis (7.93 ± 0.19 mg/mm
versus 9.61± 0.21 mg/mm; p < 0.05; Figure 1C).
We next tested if the gross regression of cardiac hypertrophy
was due to changes in cellular hypertrophy by performing
blinded morphometric analysis of cardiac histologic sections
(Figure 2A). We found no significant difference in left ventricle
(LV) cardiac myocyte cross-sectional area in young mice from
any of the three experimental conditions (186.7 ± 4.9 mm2 in Y,
243.1 ± 12.1 mm2 in Y-IP, 232.2 ± 16.4 mm2 in Y-HP). As expected
from published data by Dai et al. (2009), the average cardiacCell 153, 828–839, May 9, 2013 ª2013 Elsevier Inc. 829
Figure 2. Reversal of Age-Related Cardio-
myocyte Hypertrophy by Exposure to a
Young Circulation
(A) PAS staining of LVs 4 weeks after parabiosis
surgery is presented. Myocytes of aged mice
exposed to a young circulation (old hetero-
chronics) are smaller compared to old isochronic
controls. Scale bar, 20 mm.
(B) Graph represents cardiomyocyte (CM) cross-
sectional area (CSA) measured after PAS staining
in female mice. Myocyte size was determined from
CSA measurements of 100–200 myocytes per
animal in five independent myocardial sections.
Results are based on the average CSA from 4 to 12
animals per group.
(C) The same experiment as in (B) was performed
using male mice.
Data are shown as mean ± SEM.myocyte cross-sectional area was significantly greater in the
hearts of the old isochronic (357.8 ± 25.8 mm2) and old nonpara-
biotic controls (348.3 ± 12.6 mm2) (Figure 2B). However, aging
hearts from mice exposed to a young circulation for 4 weeks
(O-HP) showed a significant reduction in myocyte size when
compared to O-IP hearts (220.4 ± 21.9 mm2 versus 357.8 ±
25.8 mm2; p < 0.05). Thus, exposure to a young circulation re-
verses the hypertrophic cellular phenotype of aged hearts to
the morphologic phenotype typical of a young adult mouse.
To evaluate possible sex-specific effects, we repeated these
experiments using male mice and observed a similar regression
in age-related hypertrophy after exposure to a young circulation
(Figure 2C). These data indicate that gender is not a factor in the
reversal of age-related hypertrophy by a young circulation. Thus,
age-dependent cardiac hypertrophy may be reversed in both
males and females through the activity of systemic factors,
and the striking impact of such youthful factors on this age-
related pathology is apparent with only 4 weeks of parabiosis.
The Reversal of Cardiac Hypertrophy in Old Mice
Exposed to a Young Circulation Is Not Explained
by a Reduction in Blood Pressure
A crucial question raised by these data is whether a hemody-
namic effect may mediate the reduced cardiac hypertrophy
seen in aged mice following heterochronic parabiosis. To
explore the hemodynamic issue in the setting of parabiosis, we
generated female HP pairs (young, 2 months; old, 21 months)
and compared them with equal numbers of young and old IP830 Cell 153, 828–839, May 9, 2013 ª2013 Elsevier Inc.pairs and with sex- and age-matched
nonparabiotic controls using congenic
markers to confirm development of
cross-circulation (Figure S2A).
Micewere joined for 10weeks, and dur-
ing this period, we performed noninvasive
blood pressure measurements using a
computerized tail-cuff system (BP-2000;
Visitech Systems, Apex, NC, USA) (Krege
et al., 1995) that wemodified to hold para-
biotic mice (Figure 3A). In nonparabiosedcontrols (Figure 3B), we observed a significantly lower systolic
bloodpressure inaged femalemice (23monthsoldand21months
old, n = 32) compared to young (8 weeks old) CD45.2 females
(n = 12) (98.3 ± 1.8 mmHg versus 129.9 ± 2.0 mmHg; p < 0.05),
but we saw no difference when comparing aged CD45.2 to
young CD45.1 female mice (n = 16) (98.3 ± 1.8 mmHg versus
104.1 ± 1.9 mmHg; p = not significant [ns]). There were no differ-
ences in heart rate between the groups (Figure 3B). These data
suggest that differences in blood pressure or heart rate at the
time of study entry are unlikely to explain the ensuing changes in
myocyte size and global ventricular mass seen in O-HP mice.
To further address the possible impact of hemodynamic
changes in the parabiotic mice, we also performed noninvasive
blood pressure measurements at serial time points on hetero-
chronic pairs and compared them to isochronic young and old
pairs over 10 weeks. We detected no change over time in the
blood pressure of youngmice from any of the groups (Figure 3C).
In contrast, aged mice exposed to a young circulation (O-HP)
showed a significant increase in systolic blood pressure at 7
and 10 weeks, and aged members of isochronic pairs exhibited
significantly increased blood pressure at 7 weeks, relative to
baseline measurements. Finally, we obtained terminal intra-
arterial hemodynamic tracings using simultaneous microman-
ometer catheterizations, performed after mice had been joined
for 10 weeks (Figure 3D). In these studies, mean arterial pressure
did not differ significantly among any of the groups (Figure 3E).
Cross-circulation was confirmed after euthanasia by measuring
the frequency of donor-derived blood cells from one partner
Figure 3. Reversal of Cardiac Hypertrophy
in Old Mice Exposed to a Young Circulation
Cannot Be Explained by a Reduction in
Blood Pressure
(A) Systolic blood pressure was measured using a
computerized tail-cuff system that we modified to
allow simultaneous blood pressure measurement
of both members of the parabiotic pair.
(B) Systolic blood pressure (BP) and heart rate
were measured at baseline on unoperated young
and old mice. Young (2 months) CD45.2 mice
show a significantly higher systolic blood pressure
when compared to young CD45.1 (2 months) mice
and old (21 months) mice with no difference
between young CD45.1 and old mice and no
difference in heart rate among all groups.
(C) Using the system shown in (A), blood pressure
was measured simultaneously in each member of
the indicated parabiotic pair at 4, 7, and 10 weeks
after mice were conjoined. O-HP mice showed a
significant increase in systolic blood pressure at 7
and 10weeks; O-IPmice had a significant increase
in blood pressure at 7 weeks when compared to
baseline values. *p < 0.05
(D) Mean arterial pressure was determined by
performing terminal intra-arterial catheterizations
obtained simultaneously on paired mice after they
had been conjoined for 10 weeks.
(E) No significant intergroup differences in blood
pressure were detected with terminal intra-arterial
catheter-based measurements.
Data are shown as mean ± SEM. See also
Figure S2.(CD45.1+) in the spleen of the other partner (CD45.2+) (data not
shown), and evaluation of cardiac mass confirmed that O-HP
mice in this 10 week experiment also showed significant reduc-
tion in the heart weight-tibia length index when compared to the
old controls (Figure S2B). In addition, cardiac size was unaltered
in young mice joined for 10 weeks to an old partner, indicating
that prolonged exposure to an aged circulation did not induce
hypertrophy in young mice, as might be predicted if young
mice were serving as a sink for a hypertrophic factor produced
by the old mice (Figure S2B). Finally, consistent with these direct
measurements of blood pressure in parabiotic mice, circulating
levels of angiotensin II and aldosterone were not different in
animals involved in heterochronic parabiosis as compared to
their age-matched counterparts joined in isochronic parabiosis
(data not shown). Thus, it is unlikely that changes in the renin-
angiotensin-aldosterone (RAA) axis, well known for its ability to
regulate blood pressure and volume, contribute to remodeling
of the myocardium in aged heterochronic parabionts.
Taken together, these data clearly demonstrate that the
observed reversal of cardiac hypertrophy in old mice exposed
to a young circulation cannot be explained by a simple reduction
in blood pressure or modulation of known effectors of blood
pressure in the older mice. These data further implicate an anti-
hypertrophic factor produced by youngmice (rather than dilution
of a prohypertrophy factor produced by old mice) in the cardiac
remodeling induced by heterochronic parabiosis.Differences in Blood Pressure between Young CD45.1
and CD45.2Mice Do Not Explain the Reversal of Cardiac
Hypertrophy
Because young CD45.1 mice have a significantly lower blood
pressure at baseline when compared to young CD45.2 mice,
we repeated our parabiosis experiments using exclusively
CD45.2 mice to generate heterochronic pairs in which young
CD45.2 female mice (Y-HP, 2 months) were joined to aged
CD45.2 partners (O-HP, 23 months). We compared these heter-
ochronic mice to isochronic pairs (Y-IP, 2 months, or O-IP,
23 months) after 4 weeks of parabiosis. Because the mice in
this experiment were genetically identical, we could not use
flow cytometry to verify the establishment of chimerism in these
pairs; however, extensive experience with this model strongly
supports the conclusion that cross-circulation is effectively
established in fully isogenic pairs (Pietramaggiori et al., 2009).
As in our prior studies, exposure to the circulation of young
CD45.2 mice via parabiosis led to a reduction of heart weight-
to-tibia length ratio in O-HP CD45.2 mice (n = 18) when
compared to O-IP animals (n = 22) (8.03 ± 0.38 mg/mm versus
9.07 ± 0.24 mg/mm; p < 0.05, Figure 4A). Cardiomyocyte
cross-sectional area was also significantly reduced in O-HP
mice when compared to O-IP (286.3 ± 22.7 mm2 versus
366.4 ± 25.4 mm2; p < 0.05; Figure 4B). Aged partners of hetero-
chronic pairings using only CD45.2 mice also showed a blood
pressure profile after 4 weeks that was comparable to O-HPCell 153, 828–839, May 9, 2013 ª2013 Elsevier Inc. 831
Figure 4. Differences in Blood Pressure
between Young CD45.1 and CD45.2 Mice
Do Not Explain the Reversal of Cardiac
Hypertrophy
(A) Graph represents the heart weight-to-tibia
length ratio after 4 weeks of parabiosis using only
CD45.2 mice.
(B) Left ventricular myocyte cross-sectional
area based on PAS staining in CD45.2 mice is
shown. Exposure of an old mouse to the circula-
tion of a young CD45.2 mouse reverses cardiac
hypertrophy.
(C) Oldmice conjoined to young CD45.1 or CD45.2
mice show no difference in blood pressure
measured by the tail-cuff system (Figure 3A) after
4 weeks.
(D) No significant intergroup differences in blood
pressure were detected with terminal intra-arterial
catheter-based measurements.
Data are shown as mean ± SEM.mice that had been joined to young CD45.1 partners (Figures 4C
and 4D). Also, similar to results obtained using CD45.1 young
partners, heterochronic parabiosis induced no changes in heart
weight-to-tibia ratio (Figure 4A), cardiomyocyte size (Figure 4B),
or blood pressure in young CD45.2 mice joined to aged partners
(Figures 4C and 4D). These data demonstrate that the regres-
sion of cardiac hypertrophy observed in old mice exposed to
a young circulation cannot be explained by the blood pres-
sure differences we observed in young CD45.1 and CD45.2
C57Bl/6 mice.
Heterochronic Parabiosis Is Associated with Molecular
Remodeling
Cardiac hypertrophy is associated with altered expression of a
number of cardiac markers. To evaluate the reversal of hypertro-
phy in O-HPmice on a molecular level, we quantified the cardiac
transcriptional expression of atrial natriuretic peptide (ANP) and
brain natriuretic peptide (BNP), molecular markers of myocyte
hypertrophy (Figures 5A and 5B). We detected a significant
reduction in ANP and BNP transcript levels in the hearts of old
mice exposed to a young circulation, as compared to the iso-
chronic age-matched controls. Interestingly, the ANP and BNP
transcript levels were lower in the old heterochronic mice
compared to young isochronic mice. We speculate that this
may reflect a process of active regression of cellular hypertro-
phy, which may be different from nonhypertrophied myocytes
in steady state. We also quantified transcript levels of sarco-832 Cell 153, 828–839, May 9, 2013 ª2013 Elsevier Inc.plasmic reticulum calcium ATPase
(SERCA-2), expression of which may
vary with age (Dai et al., 2009) and is func-
tionally important for normal diastolic
relaxation. SERCA-2 expression was
significantly increased in hearts of aged
mice exposed to a young circulation
(O-HP) when compared to O-IP controls
(Figure 5C). These data provide additional
evidence that young circulating factorsmodify discrete molecular pathways associated with cardiac
myocyte hypertrophy and diastolic function.
Behavioral Changes Associated with Parabiosis Do Not
Explain Reversal of Cardiac Hypertrophy in
Heterochronic Mice
Although the parabiosis model has been used for physiological
studies for over a century (Finerty, 1952), we considered the pos-
sibility that the physical constraints of parabiotic pairing intro-
duced behavioral changes that contributed to the observed
reversal of cardiac hypertrophy. Thus, we developed a surgical
technique that we called ‘‘sham parabiosis,’’ whereby mice are
surgically joined while leaving the skin intact, such that they do
not develop a shared circulation (Figure 6A). We generated
sham HP pairs, in which young female mice (2 months) were
joined to aged partners (23 months) and compared these to
sham IP pairs (young-young or old-old) and to age-matched het-
erochronic and IP pairs (Figures 6A–6C). The hearts of sham
pairs were analyzed after 4 weeks, as in prior experiments. In
contrast to conventional parabiotic joining, in which effective
cross-circulation was established, we found no significant differ-
ence in heart weight-to-tibia length ratio in aged mice involved in
sham heterochronic parabiosis, as compared to aged isochronic
shams (9.38 ± 0.39 mg/mm versus 9.63 ± 0.22 mg/mm; p = ns)
(Figure 6B). These data indicate that cross-circulation and ex-
change of blood-borne factors are required for reversal of age-
related cardiac hypertrophy. This finding was also confirmed at
Figure 5. Molecular Evidence for Remodeling of Aged Myocardium
by a Young Systemic Circulation
(A) ANP and (B) BNP transcript levels were significantly reduced in old mice
exposed to a young circulation when compared to old isochronic mice.
(C)SERCA-2 transcript levels were significantly higher in oldmice exposed to a
young circulation when compared to old isochronic mice. Transcript levels
measured with real-time PCR and normalized to the Y-IP group are presented.
Data are shown as mean ± SEM.the cellular level because cardiomyocyte size in aged hetero-
chronic shams did not differ from myocyte size in aged
isochronic shams (352.9 ± 18.9 mm2 versus 355.0 ± 9.5 mm2;
p = ns) (Figure 6C). Finally, we evaluated ANP, BNP, and
SERCA-2 transcript levels in sham-operated pairs. Levels of
these molecular markers of hypertrophy were either significantlyincreased (ANP) or unaltered (BNP and SERCA-2) in old hetero-
chronic shams when compared to old isochronic shams (data
not shown), indicating that the molecular remodeling associated
with reduced cardiac hypertrophy does not occur in the absence
of a shared circulation.
Growth Differentiation Factor 11 Is Reduced in the
Circulation of Aged Mice, and Youthful Levels Are
Restored by Heterochronic Parabiosis
The studies described above strongly suggest that differences in
blood-borne factors in young versus old mice underlie the
induced cardiac remodeling observed in old mice after hetero-
chronic parabiosis. To identify candidates that might account
for the regression of cardiac hypertrophy in old mice exposed
to a youthful circulation, we performed a series of screens on
serum and plasma collected from young or old mice involved
in isochronic or heterochronic parabiosis (4 weeks duration).
With plasma from old parabionts exposed to a young circulation
or from isochronic controls, we performedmetabolomic profiling
of 69 amino acids and amines; and lipidomics analysis, assess-
ing 142 lipids from 9 lipid classes: lyso-phosphatidylcholines,
lysophosphatidylethanolamines, sphingomyelins, phospha-
tidyl-cholines, diacylglycerols, cholesterol esters, phosphatidyl-
ethanolamines, phosphatidyl-inositols, and triacylglycerols.
However, we failed to detect significant differences between
heterochronic and IP mice in either the metabolomic or the
lipidomic screen (data not shown). We next performed a
broad-scale proteomics analysis (SomaLogic, Boulder, CO,
USA) using aptamer-based technology to quantitatively evaluate
plasma samples from ten young (2month) and ten old (23month)
mice. This approach revealed 13 analytes that reliably distin-
guished young mice from old mice (Table S1). Of these candi-
dates, one (growth differentiation factor 11 [GDF11], a member
of the activin/TGF-b superfamily of growth and differentiation
factors) was confirmed in analyses of isochronic and HP
mice to show differential abundance in the blood plasma of
isochronic-old versus isochronic-young pairs and a more youth-
ful expression profile in old-heterochronic animals (Figure 7A).
To elucidate possible mechanisms for age-dependent reduc-
tion in circulating GDF11, we analyzed its expression in a range
of tissues and cell populations. Our data suggest widespread
expression, as previously reported by McPherron (2010), with
the spleen showing the highest levels of GDF11 mRNA (Fig-
ure S3A). We next examined GDF11 expression as a function
of age, comparing the tissues of old (24 months) and young
(3 months) C57Bl/6 mice (Figures S3B and S3C). We detected
a significant decline in both GDF11 gene expression and
GDF11 protein levels in the spleens of old mice. These data sug-
gest that a reduction in splenic GDF11 could contribute to the
decline of circulating GDF11 in aging mice, although because
GDF11 is produced in many organs (McPherron, 2010), changes
in expression in other tissues and organs may also contribute.
GDF11 Prevents Cardiac Hypertrophy In Vitro and
Suppresses Forkhead Transcription Factor
Phosphorylation
We next tested whether GDF11 displayed antihypertrophic
properties in cultured neonatal cardiomyocytes using aCell 153, 828–839, May 9, 2013 ª2013 Elsevier Inc. 833
Figure 6. Heterochronic Sham Parabiosis
Does Not Reverse Cardiac Hypertrophy in
Aged Mice
(A) Flow cytometry plots depicting CD45.1 (y axis)
or CD45.2 expression (x axis) by splenocytes
isolated from young or old mice joined by sham
heterochronic parabiosis are presented. Sham
parabiotic pairs showed no cross-circulation of
partner-derived blood cells as is observed in
experimental parabiosis (see Figure S1).
(B) Graph represents the heart weight-to-tibia
length ratio after 4 weeks of sham parabiosis.
(C) Left ventricular myocyte cross-sectional area
based on PAS staining after 4 weeks of sham
parabiosis is presented.
Data are shown as mean ± SEM.leucine-incorporation assay. After serum starvation, neonatal rat
cardiomyocytes were treated for 24 hr with recombinant GDF11
(rGDF11) or the closely related TGF-b superfamily protein myo-
statin at three different concentrations, followed by 24 hr expo-
sure to [3H]leucine and phenylephrine (50 mM). We observed a
significant and reproducible inhibition of phenylephrine-induced
[3H]leucine incorporation in myocytes treated with 50 nM
rGDF11, an effect that was not observed after treatment withmy-
ostatin at the same concentration (Figure 7B). We also tested the
ability of rGDF11 or myostatin to activate TGF-b pathways in
human-induced pluripotent stem cell-derived cardiomyocytes,
as previously shown in noncardiac tissues by Tsuchida et al.
(2008). Cells were stimulated for 15 min with serum-free media
(Figure 7B, Control) or with the same media containing rGDF11
(50 nM) or myostatin (50 nM). Cells stimulated with rGDF11 or
with myostatin exhibited a significant increase in pSMAD2 and
pSMAD3, consistent with activation of TGF-b pathway, and sup-
pression of Forkhead transcription factor phosphorylation (Fig-
ure 7C). Taken together, these data suggest that GDF11 has a
direct antihypertrophic effect at the level of the cardiac myocyte.
GDF11 Reverses Age-Related Cardiac Hypertrophy
In Vivo
Immunohistochemical staining of mouse cardiac sections with
antibodies specific for GDF11 demonstrated evidence for
GDF11 at the intercalated discs (Figure S4) between adjacent
cardiomyocytes, a region on the plasma membrane where other834 Cell 153, 828–839, May 9, 2013 ª2013 Elsevier Inc.ligand/receptor interactions have been
shown to affect hypertrophic signaling
pathways (Gustafson-Wagner et al.,
2007; Johnston et al., 2009). These data,
together with in vitro evidence (Figures
7B and 7C) showing GDF11-dependent
signaling in cardiomyocytes, provided
the rationale to test whether restoring
youthful levels of circulating GDF11 in
aged mice might reverse age-related
cardiac hypertrophy. To determine the
optimal dosage, route, and interval of
administration of rGDF11, we first per-
formed a dose-response study, adminis-tering the protein to mice by bolus intraperitoneal (i.p.) injection
at doses ranging from 0.005 to 0.1 mg/kg (data not shown).
Only at the highest dose (0.1 mg/kg) did we observe a repro-
ducible increase in the plasma level of GDF11 1 hr after injection
(Figure S5). Furthermore, analysis of plasma samples collected
serially over 48 hr after a single i.p. administration of 0.1 mg/kg
rGDF11 indicated that GDF11 levels were persistently elevated
for approximately 24 hr after this single injection (Figure S5).
Based on these results, we designed a randomized,
blinded, vehicle-controlled study to test the effects of rGDF11
on gross and histologic parameters of cardiac hypertrophy.
Old (23-month-old) female mice (C57Bl/6) received a daily i.p.
injection of rGDF11 (0.1 mg/kg) or saline for 30 days (n = 16
per group). The heart weight-to-tibia length ratio was sig-
nificantly lower in old mice injected with rGDF11 compared to
the saline-injected control group (Figure 7D). Morphometric
analysis further demonstrated that rGDF11 treatment resulted
in significantly smaller cardiomyocytes compared to saline-
injected controls (Figure 7E).
We also investigated molecular changes in the hearts of
rGDF11-treated aged mice. We detected a significant reduction
in BNP and a similar trend in ANP, both molecular markers
associated with cardiac hypertrophy (Figure 7F). Conversely,
SERCA-2 transcript levels, which correlate with diastolic func-
tion (Dai et al., 2009), were increased in rGDF11-treated hearts
relative to saline-treated age-matched controls. This pattern of
rGDF11-induced decrease in molecular markers of hypertrophy
Figure 7. Circulating Levels of GDF11
Are Reduced in Aged Mice, and Restor-
ing GDF11 to Youthful Levels Promotes
Reversal of Cardiac Hypertrophy and
Molecular Remodeling
(A) Western blot analysis shows reduced levels of
GDF11 in the plasma of old mice compared to
young mice (n = 3 per group). Similarly, GDF11 is
reduced in the plasma of old isochronic (O-IP)
compared to young isochronic (Y-IP) mice and is
restored to youthful levels in old mice after expo-
sure to a young circulation (O-HP) (n = 3 per
group).
(B) Phenylephrine-induced cardiac hypertrophy
measured by [3H]leucine incorporation in cardiac
myocytes exposed to rGDF11 or myostatin is
shown. rGDF11 (50 nM) prevented phenylephrine-
induced [3H]leucine incorporation.
(C) GDF11 signals through a TGF-b pathway and
suppresses Forkhead transcription factor phos-
phorylation in human cardiomyocytes. Western
blots of human-induced pluripotent stem cell-
derived cardiomyocytes stimulated for 15min with
serum-freemedia (Control) or with the samemedia
containing the indicated proteins are presented.
(D) Randomized, vehicle-controlled study of
rGDF11 therapy in aged (23 months) mice is pre-
sented. rGDF11 (0.1 mg/kg) or saline (vehicle
control) was administered by daily i.p. injection for
30 days. Graph represents heart weight-to-tibia
length ratio.
(E) Left ventricular myocyte cross-sectional area
measured after PAS staining is shown. rGDF11
therapy leads to a reduction in myocyte cross-
sectional area.
(F) Expression of ANP, BNP, or SERCA-2 in hearts
harvested from old mice treated with rGDF11 or
saline is presented. Real-time PCR transcript
measurements are normalized to levels in the
saline group.
Data are shown as mean ± SEM. See also Figures
S3, S4, S5, and S6.and increase in SERCA-2 expression resembles the pattern
observed in old mice exposed to a young circulation by para-
biosis. We also performed echocardiographic evaluation of
24-month-old male C56Bl/6 mice that were randomized to
receive a daily i.p. injection of rGDF11 (0.1 mg/kg) or vehicle
for 30 days. None of the functional parameters we evaluated
was significantly different between the two groups (Table S2).
GDF11 Does Not Prevent Cardiac Hypertrophy after
Pressure Overload In Vivo
To determine if the effect of GDF11 on cardiomyocytes is
specific for age-related cardiac hypertrophy, 2-month-old
female C56Bl/6 mice were subjected to transverse aortic
constriction and then randomized to receive a daily i.p. injection
of rGDF11 (0.1 mg/kg) or vehicle for 30 days. We performed an
echocardiographic evaluation at 15 days and then prior to sacri-
fice (Figure S6C). After 30 days, mice were euthanized, andhearts were collected for histological and molecular evaluation.
We evaluated cardiac morphometry by measuring the heart
weight-to-tibia length ratio: there was no significant reduction
in hypertrophy in mice subjected to aortic banding and treated
for 30 days with rGDF11 (n = 10) as compared with hearts of
mice that received only vehicle (n = 9) (p = 0.4; Figure S6A).
Furthermore, cardiomyocyte cross-sectional area was not
significantly different (Figure S6B). We also evaluated develop-
ment of cardiac fibrosis and did not detect any difference
between the two groups (data not shown). These data suggest
that GDF11 does not prevent all forms of cardiac hypertrophy.
DISCUSSION
Left ventricular hypertrophy is an important feature of cardiac
aging, contributing to diastolic dysfunction and heart failure
with preserved systolic function (Lakatta and Levy, 2003).Cell 153, 828–839, May 9, 2013 ª2013 Elsevier Inc. 835
An autopsy study of elderly subjects without hypertension or
clinically evident cardiovascular disease performed by Anversa
and colleagues describes cardiomyocyte enlargement and
decreased cardiomyocyte number, without a change in total
myocardial mass, a pattern that was more pronounced in males
(Olivetti et al., 1995). A cross-sectional study of a similar patient
population, however, suggests an increase in left ventricular wall
thickness in both sexes (Lakatta and Levy, 2003). Patients with
diastolic dysfunction tend to be older and are more likely to be
obese, diabetic, hypertensive, and female, compared to patients
with systolic dysfunction (Owan and Redfield, 2005), suggesting
distinct underlying pathological mechanisms.
The central hypothesis of this study is that the aging cardiac
phenotype is reversible upon exposure to factors in a young
circulation. We tested this hypothesis using surgically anasto-
mosed parabiotic mice. We chose to use C56Bl/6 mice for these
experiments because they develop an age-related cardiac
phenotype that resembles humans. In addition, because gender
can play a role in physiologic cardiac hypertrophy (Foryst-
Ludwig et al., 2011), we performed experiments in both males
and females. We found that exposure of old mice to a young
circulation via parabiosis reproducibly led to a reversal of
cardiac myocyte hypertrophy in a gender-independent fashion
and that this reduced cardiomyocyte size translated into a
reduction in global cardiac mass. This structural transformation
was accompanied by a reduction in myocardial gene expression
of natriuretic peptides known to promote maladaptive cardiac
remodeling and an increase in Ca2+ ATPase (SERCA-2), the
expression of which is integral to myocardial relaxation and
hence normal diastolic function. Together, these data are
consistent with the concept that factors present in a young
circulation can reverse critical structural and molecular aspects
of cardiac aging.
With circulatory transfer of a soluble substance emerging as a
likely mechanism of cardiac hypertrophy regression in old para-
biotic mice, we performed a systematic search to identify candi-
date factors present at higher levels in the blood of young mice
that might underlie the antihypertrophic effect. Our proteomic
analysis identified several factors with levels that change with
age, and we cannot exclude the possibility that other factors
also participate in the effect observed in heterochronic parabi-
osis; however, GDF11 emerged as a strong candidate from a
series of screening analyses comparing the lipid profiles, metab-
olites, and signaling proteins present in young versus old
plasma. Although GDF11 expression is detectable in a range of
tissues, the spleen shows the highest concentration and exhibits
an age-dependent decline inGDF11 levels. Thus, the spleenmay
contribute to circulating GDF11, and an age-related production
or secretory defect in the spleen could participate in the reduc-
tion in circulating GDF11 in old mice.
A recent study shows that the treatment of cachexic mice with
soluble ActRIIB protein (sActRIIB), which antagonizes signaling
by GDF11 (as well as myostatin, activin, and other TGF-b family
members, given the promiscuity of the receptors; Tsuchida et al.,
2008) reverses cardiac atrophy in tumor-bearing animals (Zhou
et al., 2010). Together with our proteomic data, this study further
supported the notion that GDF11 acts as a mediator of the sys-
temic antihypertrophic activity found in young mice. Moreover,836 Cell 153, 828–839, May 9, 2013 ª2013 Elsevier Inc.our histological data (Figure S4) suggested binding of GDF11
to cardiomyocytes in vivo. We therefore performed a random-
ized, vehicle-controlled study, administering rGDF11 to old
mice for 30 days. This rGDF11 therapy led to a significant regres-
sion of cardiac hypertrophy in old mice, as indicated by both
heart weight measurements and morphometric analyses.
Moreover, the demonstration that rGDF11, but not myostatin,
induced a dose-dependent inhibition of phenylephrine-mediated
hypertrophy in neonatal cardiacmyocytes, in vitro, suggests that
GDF11 has specific and direct effects at the level of the cardiac
myocyte. However, both rGDF11 and myostatin stimulated
TGF-b signaling pathways, including antihypertrophic FoxO
factors. Although it is plausible that the antihypertrophic effect
of rGDF11 is mediated by FoxO-dependent proteasome-
mediated protein degradation (Sandri et al., 2004), our data do
not explain the differential effects of rGDF11 and myostatin.
We speculate that the differential effect may be due to differ-
ences in the activity of endogenous inhibitors and/or subtle
differences in receptor affinity (Mueller and Nickel, 2012).
The observation that myostatin negatively regulates skeletal
muscle mass led to the development of therapeutic strategies
for age- and cancer-related muscle atrophy by blocking myo-
statin signaling. Interestingly, although myostatin null mice have
not consistently demonstrated important changes in cardiac
mass during aging (Cohn et al., 2007; Jackson et al., 2012), treat-
ment with a soluble ActRIIB antagonist leads to increased
skeletal and cardiac muscle mass, suggesting that the cardiac
effects of this antagonist may arise from inhibition of a ligand
other than myostatin. Indeed, despite signaling through similar
activin receptor combinations, GDF11 and myostatin exhibit
many nonoverlapping functions. Myostatin null mice demon-
strate substantially increased skeletal muscle mass, whereas
GDF11 null mice exhibit skeletal and renal abnormalities and
die within 24 hr of birth (McPherron et al., 1999). Thus, we spec-
ulate that the reported ActRIIB antagonist effects on myocar-
dium (Zhou et al., 2010) may be due to inhibition of GDF11
signaling and independent of effects on myostatin. Our data
demonstrate thatGDF11 andmyostatin share some in vitro prop-
erties; apparent in vivo differences are not yet fully understood.
GDF11 was ineffective in preventing cardiac hypertrophy in
the context of pressure overload, suggesting that the antihyper-
trophic properties of GDF11 may not be generalizable to all
forms of cardiac hypertrophy. Interestingly, our preliminary
studies suggest that GDF11 treatment may influence aging
phenotypes in other tissues, such as skeletal muscle, and further
investigations will be important for determining the role of GDF11
in aging beyond the heart.
In summary, our analysis of reverse remodeling in the hearts of
HP mice led to the identification of GDF11 as an age-regulated
circulating factor with potent antihypertrophic properties. Our
studies implicate GDF11 in age-related cardiac hypertrophy
but do not exclude participation of other factors (Table S1), nor
do we have direct evidence indicating a role for GDF11 in the
development of age-related cardiac hypertrophy in humans,
although GDF11 does stimulate phosphorylation of target
protein (SMAD2/SMAD3) in human pluripotent cell-derived
cardiomyocytes (Figure 7C). Recently identified in the circulation
of humans (Souza et al., 2008), GDF11, like other TGF-b family
members, circulates at significantly lower concentrations in
humans compared to mice (Souza et al., 2008). Using a pro-
teomic approach, Ganz and colleagues have reported prelimi-
nary data that low levels of GDF11 identify a cohort among
humans with stable coronary artery disease with a higher risk
for composite endpoint of all-cause mortality, myocardial infarc-
tion, heart failure, and stroke (P. Ganz et al., 2012, Am. Heart
Assoc. Sci., conference). Future studies will be necessary to
evaluate the role of GDF11 in human cardiac hypertrophy. We
recognize that cardiac hypertrophy of aging is a multifactorial
process and that the observed regression of cardiac hypertro-
phy in old mice exposed to a young circulation is unlikely to be
attributable entirely to the replenishment of a single factor. None-
theless, our results suggest exciting therapeutic possibilities for
targeting cardiac hypertrophy of aging by restoring youthful
levels of circulating GDF11.
EXPERIMENTAL PROCEDURES
Animals
Aged (21–23 months) C57Bl/6 mice were obtained from the National Institute
on Aging (NIA); young (2 months) C57Bl/6 (CD45.1CD45.2+) or young B6.SJL
(CD45.1+CD45.2) mice were obtained from JAX. Maintenance of mouse
colonies and all experiments were conducted in accordance with the Guide
for the Use and Care of Laboratory Animals and approved by the Harvard
Medical Area Standing Committee on Animals.
Parabiosis
Parabiosis was performed as described previously by Bunster and Meyer
(1933) and Ruckh et al. (2012). Blood chimerism was confirmed in a subset
of parabiotic pairs by flow cytometry measuring the frequency of donor-
derived blood cells from one partner (CD45.1+) in the spleen of the other
partner (CD45.2+). Partner-derived cells typically represented 40%–50% of
splenocytes, consistent with establishment of parabiotic cross-circulation.
Because old CD45.1+ mice are not commercially available, we could not
use this method to verify the establishment of chimerism in isochronic-old
parabiotic pairs.
Sham Parabiosis
Sham parabiosis was performed as amodification of the parabiosis procedure
(Bunster and Meyer, 1933;Ruckh et al., 2012) to achieve surgical joining
without development of a shared circulation. Mice were anesthetized to full-
muscle relaxation and joined by a modification of the technique of Bunster
and Meyer (1933). After shaving the corresponding lateral aspects of each
mouse,matching skin incisions weremade from the olecranon to the knee joint
of each mouse, and the subcutaneous fascia was bluntly dissected to create
about 0.5 cm of free skin. The olecranon and knee joints were attached with a
single 2-0 Prolene suture. The suture was sequentially passed through the skin
and joint of the firstmouse, through a silicon disk to separate the skin of the two
mice, and then through the skin and joint of the secondmouse. The suture was
tied, such that the silicon disk separated the skin of eachmouse at the joint and
without any contact between the cutaneous flaps of each mouse. The skin
incisions were closed with staples. The Prolene sutures connecting the mice
were reinforced with meshed staples.
Western Blot, Flow Cytometry, Gene Expression, and Metabolomic
and Lipidomic-Profiling Analysis
Please refer to Extended Experimental Procedures.
Morphometric Assessment of Cardiomyocyte Size
Mouse hearts were fixed with 4% paraformaldehyde, paraffin embedded,
sectioned, and stained with periodic acid Schiff (PAS). Staining, scanning,
and quantification were carried out in a blinded manner using five randomly
selected sections from the heart.Noninvasive Blood Pressure
We used a computerized tail-cuff system (BP-2000) that we modified to allow
simultaneous blood pressure measurement of both members of the parabiotic
pair. Unoperated mice or pairs of mice were trained for 5 consecutive days in
the prewarmed tail-cuff device to accustom them to the procedure, followed
by measurements of heart rate and systolic blood pressure.
Neurohormonal Measurements
Circulating levels of angiotensin II and aldosterone in serum samples were
measured by ELISA (Enzo Life Sciences International, USA).
Proteomic Analysis
EDTA plasma samples (20 ml) from 20 mice were analyzed on the SomaLogic
proteomics discovery platform (SOMAscan), which uses SOMAmers to
measure 1,001 proteins simultaneously. SOMAmers (Slow Off-rate Modified
Aptamers) are nucleic acid-based protein binding reagents evolved through
SELEX (Tuerk and Gold, 1990) to bind protein targets. SOMAscan transforms
the concentration of proteins in thematrix into a relative quantity of SOMAmers,
through equilibration binding and removal of unbound SOMAmers and
proteins. The SOMAmer quantity is measured by hybridization to microarrays
(for a full description, see Gold et al., 2010).
In Vitro Cardiac Myocyte Hypertrophy Assay
Neonatal cardiac myocytes were isolated from postnatal day 1 CD1 rats
(Charles River) (Seki et al., 2009). Approximately 36 hr after plating, cardiac
myocytes were serum starved for 24 hr in low-glucose DMEM supplemented
with ITS (PAA Laboratories). Cardiacmyocytes were pretreatedwith myostatin
(R&D Systems) or rGDF11 (PeproTech) for 24 hr, prior to treating with phenyl-
ephrine (50 mM; Sigma-Aldrich) and assaying protein synthesis/hypertrophy
with [3H]leucine (1 mCi/ml; Moravek). rGDF11 and myostatin treatments were
continued during the period of exposure to phenylephrine and [3H]leucine.
Twenty-four hours after labeling with [3H]leucine, cells were washed with
ice-cold PBS and fixed with ice-cold 10% trichloroacetic acid for 45 min at
4C. Cells were lysed with 0.05 M NaOH and analyzed by liquid scintillation.
Induced Pluripotent Stem-Cell-Derived Human Cardiomyocytes
Please refer to Extended Experimental Procedures for induced pluripotent
stem cell-derived human cardiomyocytes.
Transverse Aortic Constriction and Echocardiography
Please refer to Extended Experimental Procedures for the transverse aortic
constriction and echocardiography procedures.
Statistical Analyses
Data comparison was subjected to one-way ANOVA and post hoc Bonferroni
correction or Student’s t test assuming two-tailed distribution and unequal
variances. Statistical significance was assigned for p < 0.05; results are shown
as SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
six figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2013.04.015.
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